Teacher Retirement System of Texas Has $114,000 Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Teacher Retirement System of Texas grew its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 37.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,254 shares of the company’s stock after purchasing an additional 5,512 shares during the quarter. Teacher Retirement System of Texas’ holdings in Verve Therapeutics were worth $114,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. State Street Corp lifted its position in Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after buying an additional 903,809 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Verve Therapeutics by 2.6% during the third quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company’s stock worth $7,749,000 after purchasing an additional 40,915 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Verve Therapeutics by 72.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock valued at $7,547,000 after purchasing an additional 653,578 shares during the last quarter. FMR LLC increased its holdings in shares of Verve Therapeutics by 0.3% in the third quarter. FMR LLC now owns 1,418,993 shares of the company’s stock valued at $6,868,000 after purchasing an additional 3,873 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Verve Therapeutics by 28.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after purchasing an additional 126,110 shares in the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Performance

VERV opened at $3.91 on Thursday. Verve Therapeutics, Inc. has a twelve month low of $3.77 and a twelve month high of $9.31. The firm has a market cap of $347.19 million, a PE ratio of -1.59 and a beta of 1.77. The firm’s fifty day moving average is $6.78 and its two-hundred day moving average is $6.05.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.14. The business had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on VERV shares. Guggenheim restated a “buy” rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada dropped their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.50.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.